» Articles » PMID: 17321001

Hepatic Gene Expression and Lipid Parameters in Complement C3(-/-) Mice That Do Not Develop Ethanol-induced Steatosis

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2007 Feb 27
PMID 17321001
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: Fatty infiltration initiates alcohol-induced liver changes and complement component C3 affects lipid metabolism. We recently observed that ethanol-induced steatosis seen in normal (C3(+/+)) mice was absent in livers of C3-deficient (C3(-/-)) mice. To understand the underlying molecular mechanisms we analyzed lipid parameters and liver gene expression profiles in these mice.

Methods: A Western-type high-fat diet with ethanol or carbohydrates (control) was fed for 6 weeks to C3(+/+) and C3(-/-) mice. Serum and liver lipid parameters were analyzed and liver mRNA expression patterns studied by micro-array analysis and RT-PCR.

Results: In both genotypes ethanol markedly reduced serum cholesterol, apolipoprotein A-I, phospholipid transfer protein activity and hepatic mRNA levels of fatty acid-binding proteins and fatty acid beta-oxidation enzymes. In contrast, exclusively in C3(-/-) mice, ethanol treatment increased serum and liver adiponectin levels but down-regulated transcripts of lipogenic enzymes, adiponectin receptor 2 and adipose differentiation-related protein and up-regulated phospholipase D1.

Conclusions: We propose that these ethanol-induced alterations observed exclusively in C3(-/-) mice contribute to protection against fatty infiltration and subsequent inflammatory processes in the liver of these mice. The results suggest important cross-talk between complement factor C3 and lipid regulators in ethanol-induced steatosis.

Citing Articles

The unique role of innate lymphoid cells in cancer and the hepatic microenvironment.

Curio S, Belz G Cell Mol Immunol. 2022; 19(9):1012-1029.

PMID: 35962192 PMC: 9424527. DOI: 10.1038/s41423-022-00901-1.


Comprehensive RNA-Seq Analysis of Potential Therapeutic Targets of Gan-Dou-Fu-Mu Decoction for Treatment of Wilson Disease Using a Toxic Milk Mouse Model.

Wei T, Hao W, Tang L, Wu H, Huang S, Yang Y Front Pharmacol. 2021; 12:622268.

PMID: 33935715 PMC: 8082393. DOI: 10.3389/fphar.2021.622268.


Comparing the inflammatory profiles for incidence of diabetes mellitus and cardiovascular diseases: a prospective study exploring the 'common soil' hypothesis.

Bao X, Borne Y, Johnson L, Muhammad I, Persson M, Niu K Cardiovasc Diabetol. 2018; 17(1):87.

PMID: 29895294 PMC: 5996509. DOI: 10.1186/s12933-018-0733-9.


Reduced bone loss in a murine model of postmenopausal osteoporosis lacking complement component 3.

MacKay D, Kean T, Bernardi K, Haeberle H, Ambrose C, Lin F J Orthop Res. 2017; 36(1):118-128.

PMID: 28667799 PMC: 5758433. DOI: 10.1002/jor.23643.


Targeting inflammation for the treatment of alcoholic liver disease.

Xu M, Zhou Z, Parker R, Gao B Pharmacol Ther. 2017; 180:77-89.

PMID: 28642119 PMC: 5677537. DOI: 10.1016/j.pharmthera.2017.06.007.